Biogen Inc. (NASDAQ: BIIB) reported first quarter 2022 earnings results today. Total revenue decreased 6% year-over-year to $2.53 billion. GAAP net income attributable to Biogen Inc. was $304 million, or $2.06 per share, compared to $410 million, or $2.69 per share, last year. Adjusted EPS amounted to $3.62. For full-year 2022, total revenue is estimated to […]
Biogen Inc. (NASDAQ: BIIB) reported first quarter 2022 earnings results today. Total revenue decreased 6% year-over-year to $2.53 billion. GAAP net income attributable to Biogen Inc. was $304 million, or $2.06 per share, compared to $410 million, or $2.69 per share, last year. Adjusted EPS amounted to $3.62. For full-year 2022, total revenue is estimated to […]
Biogen Inc. (NASDAQ: BIIB) reported first quarter 2022 earnings results today.
Total revenue decreased 6% year-over-year to $2.53 billion.
GAAP net income attributable to Biogen Inc. was $304 million, or $2.06 per share, compared to $410 million, or $2.69 per share, last year. Adjusted EPS amounted to $3.62.
For full-year 2022, total revenue is estimated to be $9.7-10 billion while adjusted EPS is expected to be $14.25-16.00.
